Vaxcyte (PCVX) Capital Expenditures (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Capital Expenditures data on file, last reported at $6.3 million in Q1 2026.

• Capital Expenditures for Q1 2026 came in at $6.3 million, up 63.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.0 million (down 12.27% YoY), and the FY2025 annual result was $7.5 million, down 42.8% from the prior year.
• Capital Expenditures climbed to $6.3 million in Q1 2026 per PCVX's latest filing, from $2.0 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $13.1 million in Q3 2024 and troughed at -$5.2 million in Q4 2024.
• A 5-year average of $2.9 million and a median of $2.1 million in 2025 frame the typical range for Capital Expenditures.
• On a YoY basis, Capital Expenditures climbed as much as 9861.4% in 2024 and fell as far as 199.49% in 2024.
• A 5-year view of Capital Expenditures shows it stood at $1.1 million in 2022, then jumped by 360.88% to $5.3 million in 2023, then tumbled by 199.49% to -$5.2 million in 2024, then soared by 137.69% to $2.0 million in 2025, then surged by 221.98% to $6.3 million in 2026.
• Business Quant data shows PCVX's Capital Expenditures at $6.3 million in Q1 2026, $2.0 million in Q4 2025, and $2.1 million in Q3 2025.